John Chionis

427 total citations
11 papers, 144 citations indexed

About

John Chionis is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, John Chionis has authored 11 papers receiving a total of 144 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 5 papers in Pulmonary and Respiratory Medicine and 5 papers in Oncology. Recurrent topics in John Chionis's work include Advanced Breast Cancer Therapies (5 papers), Receptor Mechanisms and Signaling (3 papers) and Cancer-related Molecular Pathways (3 papers). John Chionis is often cited by papers focused on Advanced Breast Cancer Therapies (5 papers), Receptor Mechanisms and Signaling (3 papers) and Cancer-related Molecular Pathways (3 papers). John Chionis collaborates with scholars based in United States and Switzerland. John Chionis's co-authors include Flossie Wong‐Staal, Ke Ning, Qi‐Xiang Li, Dehua Yu, Guohong Liu, Tarif Awad, Wufang Fan, Mirta Grifman, Roshni Sundaram and Jon E. Chatterton and has published in prestigious journals such as Cancer Research, Scientific Reports and Biochemical and Biophysical Research Communications.

In The Last Decade

John Chionis

10 papers receiving 137 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John Chionis United States	6	105	36	34	22	17	11	144
Carlos Moran Segura United States	8	110 1.0×	39 1.1×	24 0.7×	20 0.9×	15 0.9×	21	203
Matthew C. Sims United Kingdom	5	102 1.0×	26 0.7×	40 1.2×	19 0.9×	26 1.5×	7	181
Víctor Dumas Canada	7	205 2.0×	26 0.7×	20 0.6×	7 0.3×	14 0.8×	13	255
Laura M. McDonell Canada	6	95 0.9×	32 0.9×	9 0.3×	13 0.6×	49 2.9×	10	155
Evangeline Reynolds United States	4	75 0.7×	44 1.2×	13 0.4×	11 0.5×	8 0.5×	5	126
Adrián Sanz‐Moreno Germany	7	101 1.0×	60 1.7×	12 0.4×	15 0.7×	26 1.5×	16	171
Anja Wieland Germany	6	90 0.9×	35 1.0×	30 0.9×	21 1.0×	2 0.1×	7	147
Birgitta Birgisdottir Sweden	2	73 0.7×	71 2.0×	25 0.7×	9 0.4×	25 1.5×	2	138
Ryan W. Clinton United States	5	213 2.0×	19 0.5×	8 0.2×	10 0.5×	6 0.4×	8	255
Jonathan Belman United States	8	127 1.2×	14 0.4×	11 0.3×	15 0.7×	15 0.9×	11	231

Countries citing papers authored by John Chionis

Since Specialization

Citations

This map shows the geographic impact of John Chionis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Chionis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Chionis more than expected).

Fields of papers citing papers by John Chionis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Chionis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Chionis. The network helps show where John Chionis may publish in the future.

Co-authorship network of co-authors of John Chionis

This figure shows the co-authorship network connecting the top 25 collaborators of John Chionis. A scholar is included among the top collaborators of John Chionis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Chionis. John Chionis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Baker, Michael G., et al.. (2025). Abstract 5335: A comparative study of CDK2 inhibitors. Cancer Research. 85(8_Supplement_1). 5335–5335.

Ding, Xia, Zhou Zhu, John D. Lapek, et al.. (2022). PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib. Scientific Reports. 12(1). 12501–12501. 8 indexed citations

Chionis, John, et al.. (2016). Abstract P3-06-01: Mechanisms of resistance to CDK4/6 inhibition in ER+ breast cancer. Cancer Research. 76(4_Supplement). P3–6. 3 indexed citations

Hidalgo, Manuel, Camino Menéndez, Jing Yuan, et al.. (2015). Abstract A42: Palbociclib potentiates nab-paclitaxel efficacy in pancreatic ductal adenocarcinoma. Molecular Cancer Therapeutics. 14(12_Supplement_2). A42–A42. 1 indexed citations

Koehler, María, Todd VanArsdale, David J. Shields, et al.. (2014). Mechanism of Action for Combined CDK4/6 and Er Inhibition in ER Positive Breast Cancer. Annals of Oncology. 25. i21–i21. 5 indexed citations

Lee, Nathan V., Jing Yuan, Joan Cao, et al.. (2014). Abstract LB-136: Mechanistic exploration of combined CDK4/6 and ER inhibition in ER-positive breast cancer. Cancer Research. 74(19_Supplement). LB–136. 3 indexed citations

Ning, Ke, Roshni Sundaram, Guohong Liu, et al.. (2007). Orphan G protein–coupled receptor GPR56 plays a role in cell transformation and tumorigenesis involving the cell adhesion pathway. Molecular Cancer Therapeutics. 6(6). 1840–1850. 60 indexed citations

Ning, Ke, Hongwen Ma, Gundo Diedrich, et al.. (2007). Biochemical characterization of genetic mutations of GPR56 in patients with bilateral frontoparietal polymicrogyria (BFPP). Biochemical and Biophysical Research Communications. 366(2). 314–320. 25 indexed citations

Zhang, Jing, Cuiying Wang, Ke Ning, et al.. (2007). A more efficient RNAi inducible system for tight regulation of gene expression in mammalian cells and xenograft animals. RNA. 13(8). 1375–1383. 21 indexed citations

10.

Ning, Ke, Demin Zhou, Jon E. Chatterton, et al.. (2006). A new inducible RNAi xenograft model for assessing the staged tumor response to mTOR silencing. Experimental Cell Research. 312(15). 2726–2734. 17 indexed citations

11.

Sundaram, Roshni, Wufang Fan, Dehua Yu, et al.. (2005). Orphan G-protein coupled receptor GPCR-X as a novel cancer drug target: validation and mechanistic studies. Cancer Research. 65. 225–225. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact